JP6926192B2 - N,n−ビス−2−メルカプトエチルイソフタルアミドの新規用途 - Google Patents

N,n−ビス−2−メルカプトエチルイソフタルアミドの新規用途 Download PDF

Info

Publication number
JP6926192B2
JP6926192B2 JP2019505490A JP2019505490A JP6926192B2 JP 6926192 B2 JP6926192 B2 JP 6926192B2 JP 2019505490 A JP2019505490 A JP 2019505490A JP 2019505490 A JP2019505490 A JP 2019505490A JP 6926192 B2 JP6926192 B2 JP 6926192B2
Authority
JP
Japan
Prior art keywords
paracetamol
pharmaceutically acceptable
nbmi
toxicity
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019505490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524782A (ja
JP2019524782A5 (enExample
Inventor
ユージーン ハリー,ボイド
ユージーン ハリー,ボイド
アクセル テオドール クリングバーグ,ラグナー
アクセル テオドール クリングバーグ,ラグナー
Original Assignee
エメレイムド リミテッド
エメレイムド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エメレイムド リミテッド, エメレイムド リミテッド filed Critical エメレイムド リミテッド
Publication of JP2019524782A publication Critical patent/JP2019524782A/ja
Publication of JP2019524782A5 publication Critical patent/JP2019524782A5/ja
Application granted granted Critical
Publication of JP6926192B2 publication Critical patent/JP6926192B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2019505490A 2016-08-05 2017-08-04 N,n−ビス−2−メルカプトエチルイソフタルアミドの新規用途 Active JP6926192B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201613535 2016-08-05
GB1613535.2 2016-08-05
PCT/GB2017/052306 WO2018025049A1 (en) 2016-08-05 2017-08-04 New use of n,n-bis-2-mercaptoethyl isophthalamide

Publications (3)

Publication Number Publication Date
JP2019524782A JP2019524782A (ja) 2019-09-05
JP2019524782A5 JP2019524782A5 (enExample) 2020-09-10
JP6926192B2 true JP6926192B2 (ja) 2021-08-25

Family

ID=60202272

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019505490A Active JP6926192B2 (ja) 2016-08-05 2017-08-04 N,n−ビス−2−メルカプトエチルイソフタルアミドの新規用途

Country Status (31)

Country Link
US (2) US20190240173A1 (enExample)
EP (2) EP4029497A1 (enExample)
JP (1) JP6926192B2 (enExample)
KR (1) KR102538388B1 (enExample)
CN (1) CN109562179A (enExample)
AU (1) AU2017305661B2 (enExample)
BR (1) BR112019002130A2 (enExample)
CL (1) CL2019000229A1 (enExample)
CY (1) CY1125039T1 (enExample)
DK (1) DK3493849T3 (enExample)
EA (1) EA201990443A1 (enExample)
ES (1) ES2907838T3 (enExample)
HR (1) HRP20220252T1 (enExample)
HU (1) HUE057782T2 (enExample)
IL (1) IL264538B2 (enExample)
LT (1) LT3493849T (enExample)
MA (1) MA45855B1 (enExample)
MD (1) MD3493849T2 (enExample)
MX (1) MX387853B (enExample)
MY (1) MY199733A (enExample)
NZ (1) NZ750271A (enExample)
PH (1) PH12019500237A1 (enExample)
PL (1) PL3493849T3 (enExample)
PT (1) PT3493849T (enExample)
RS (1) RS62924B1 (enExample)
SG (1) SG11201900565RA (enExample)
SI (1) SI3493849T1 (enExample)
SM (1) SMT202200109T1 (enExample)
UA (1) UA125394C2 (enExample)
WO (1) WO2018025049A1 (enExample)
ZA (1) ZA201900594B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005057D0 (en) 2020-04-06 2020-05-20 Emeramed Ltd New Use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586600B2 (en) 2000-12-06 2003-07-01 University Of Kentucky Research Foundation Multidentate sulfur-containing ligands
US8950583B2 (en) * 2008-12-06 2015-02-10 Ermes Medical Company Limited Method to remove heavy metals from a mammal
US20120122787A1 (en) * 2009-07-10 2012-05-17 Rong Li Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases
US8575218B2 (en) 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
AU2010297933A1 (en) 2009-09-28 2012-04-19 University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from contaminated milieu and methods of use
US8426368B2 (en) 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet
US20110237776A1 (en) 2010-03-25 2011-09-29 Haley Boyd E Aromatic compounds with sulfur containing ligands

Also Published As

Publication number Publication date
MA45855B1 (fr) 2022-02-28
MA45855A (fr) 2021-03-17
EP4029497A1 (en) 2022-07-20
AU2017305661B2 (en) 2023-05-18
EA201990443A1 (ru) 2019-07-31
CY1125039T1 (el) 2023-03-24
EP3493849A1 (en) 2019-06-12
JP2019524782A (ja) 2019-09-05
PT3493849T (pt) 2022-02-23
ZA201900594B (en) 2019-08-28
RS62924B1 (sr) 2022-03-31
KR20190035724A (ko) 2019-04-03
CA3032858A1 (en) 2018-02-08
LT3493849T (lt) 2022-03-10
MX2019000978A (es) 2019-06-10
KR102538388B1 (ko) 2023-05-30
IL264538B (en) 2022-10-01
US20250325503A1 (en) 2025-10-23
PL3493849T3 (pl) 2022-03-28
US20190240173A1 (en) 2019-08-08
MD3493849T2 (ro) 2022-04-30
CL2019000229A1 (es) 2019-04-26
MX387853B (es) 2025-03-19
MY199733A (en) 2023-11-21
WO2018025049A1 (en) 2018-02-08
SMT202200109T1 (it) 2022-05-12
ES2907838T3 (es) 2022-04-26
HUE057782T2 (hu) 2022-06-28
AU2017305661A1 (en) 2019-02-14
BR112019002130A2 (pt) 2019-05-14
HRP20220252T1 (hr) 2022-04-29
IL264538B2 (en) 2023-02-01
EP3493849B1 (en) 2021-12-01
NZ750271A (en) 2025-07-25
UA125394C2 (uk) 2022-03-02
SG11201900565RA (en) 2019-02-27
SI3493849T1 (sl) 2022-04-29
PH12019500237A1 (en) 2019-10-28
CN109562179A (zh) 2019-04-02
IL264538A (enExample) 2019-03-31
DK3493849T3 (en) 2022-03-07

Similar Documents

Publication Publication Date Title
Praphanproj et al. Three cases of intravenous sodium benzoate and sodium phenylacetate toxicity occurring in the treatment of acute hyperammonaemia
JP6353577B2 (ja) 組み合わせ組成物
KR20150050595A (ko) 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
JP2003171271A (ja) 耐糖能異常用薬剤
US20250325503A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
WO1999003466A1 (fr) Substance prophylactique ou therapeutique contre l'amnesie
JP5516654B2 (ja) 肝癌発生・進展抑制剤
CA2382548C (en) Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof
US20160128954A1 (en) Methods of Treating Huntington's Disease Using Cysteamine Compositions
JP2009534360A (ja) アルファ−ケトグルタレートを含む組成物およびその筋性能を調節するための使用
JP2024016228A (ja) アセトアミノフェン(apap)によって引き起こされる毒性を予防、低減または根絶するための方法および組成物
WO2012005605A1 (en) A combination composition comprising ibuprofen and paracetamol
CA3032858C (en) Use of n,n-bis-2-mercaptoethyl isophthalamide to prevent or treat paracetamol toxicity
HK40005150B (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
JPWO2005089743A1 (ja) 腎性貧血治療剤
JP2005516976A (ja) L−メチオニンs−スルホキシイミンの新規な投与形態
Shakerdi et al. Inborn Errors of Amino Acid Metabolism Revisited: Clinical Implications and Insights into Current Therapies
US20230181498A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
BR112019005039B1 (pt) Método de redução dos efeitos colaterais associados à tireoide
JP2013147493A (ja) 安全な医薬組成物
JP2009084253A (ja) 頭痛の予防および/または治療剤

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20190327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200729

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210804

R150 Certificate of patent or registration of utility model

Ref document number: 6926192

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250